{"slug":"glp1-metabolic","topic":"glp1-metabolic","title":"GLP-1 & Incretin Therapies: State of the Field (October 2026)","summary":"Covers semaglutide, tirzepatide, the new oral GLP-1 agonists and next-generation triple-agonist and amylin-combination drugs, with their effects on weight, diabetes, cardiovascular, kidney, heart-failure, liver, sleep-apnea, joint and brain outcomes as of October 2026. The central takeaway: the field has moved from proving weight loss to proving organ protection. Placebo-adjusted mean weight loss at the top doses of pivotal trials in adults without diabetes now ranges from about 9 percentage points (oral orforglipron) to about 21 (retatrutide, not yet approved), and the main open questions are durability after stopping, lean-mass and rare safety signals, cost and access, and how much of the benefit is independent of weight loss.","version":1,"published_at":"2026-10-29","updated_at":"2026-10-29","stats":{"words":5487,"citations":100,"claims":36,"timeline":18,"benchmarks":12,"open_problems":8,"key_papers":14,"glossary":12},"verification":{"status":"verified","method":"Independent AI fact-check against cited sources: evidence-pack check of 36 claims + 124 contexts (including 18 timeline and 12 benchmark rows), 17 web checks (batch PubMed abstracts for all 89 DOI records, ClinicalTrials.gov records for 9 trials, one PMC record, agency/company announcements and trade press for regulatory and topline claims); automated citation resolution","claims_checked":36,"contexts_checked":124,"web_checks":17,"issues_fixed":31,"verified_at":"2026-10-29","notes":["Thyroid cancer: replaced \"inconclusive because events are rare\" with the 2026 review's mixed evidence (rodent-based boxed warning; three trial meta-analyses reporting an increase); pancreatic-cancer statement kept on the 2021 safety review.","SURPASS-CVOT: removed the unverifiable claim that all-cause death sat outside multiplicity-controlled testing; added the verified HR 0.84 (95% CI 0.75-0.94) with a caution.","Executive summary: SUMMIT benefit attributed to worsening-heart-failure events; cross-trial efficacy headline softened; STEP 1 extension labelled exploratory (n=327); SURMOUNT-OSA population and REDEFINE 4 estimand specified; GI adverse-event context added.","Citations re-pointed: Nature Reviews Drug Discovery review moved from a mouse-circuit claim to the lean-mass discussion; energy-intake claim now cites the two physiology reviews; OASIS 1 and OASIS 4 added for the 25-50 mg oral doses.","Company and regulatory events (FDA approvals of oral semaglutide 25 mg in Dec 2025 and orforglipron in Apr 2026, EMA NAION conclusion in Jun 2025, CMS BALANCE/Bridge changes, Nov 2025 USD 245 Medicare price, generic launches, REDEFINE 4 and TRIUMPH toplines, Q1 2027 retatrutide filing plan) were checked against agency/company announcements and trade press and stay attributed in the text, since no DOI/NCT/PMID exists for them.","Removed or softened unsupported details: CMS date (April to spring 2026, sources disagree), evoke topline date, China data-protection rationale, AMPLIFY-1 start (not yet recruiting), older-adult and heart-failure-subtype statements not in the cited abstracts, \"about four years\" follow-up.","Consistency and safety context: SUMMIT and SURMOUNT-1 3-year benchmark years changed from 2025 to 2024 to match records and timeline; estimand-gap example corrected to 2.8 and 3.3 points; comparator or severity context added to cholelithiasis, GI, gastric-content, dysesthesia and EMA NAION statements; type 1 diabetes sentence reworded so it does not read as dosing advice.","No new citation ids added; all 100 cited keys resolve to evidence-pack records. The dossier has no in-file disclaimer; the site-level not-medical-advice notice applies."]},"ai_assisted":true,"price":{"usd":"0.20","protocol":"x402","network":"eip155:84532","asset":"USDC"},"url":"https://space-kitty.com/dossiers/glp1-metabolic","preview_url":"https://space-kitty.com/api/v1/dossiers/glp1-metabolic/preview","purchase_url":"https://space-kitty.com/api/v1/dossiers/glp1-metabolic","toc":[{"level":2,"text":"Executive summary","anchor":"executive-summary"},{"level":2,"text":"Background and core concepts","anchor":"background-and-core-concepts"},{"level":2,"text":"Timeline of key milestones","anchor":"timeline-of-key-milestones"},{"level":2,"text":"State of the art","anchor":"state-of-the-art"},{"level":3,"text":"Semaglutide: injectable and oral","anchor":"semaglutide-injectable-and-oral"},{"level":3,"text":"Tirzepatide and head-to-head evidence","anchor":"tirzepatide-and-head-to-head-evidence"},{"level":3,"text":"Next-generation agents: triple agonists, amylin combinations, monthly dosing","anchor":"next-generation-agents-triple-agonists-amylin-combinations-monthly-dosing"},{"level":3,"text":"Oral small molecules","anchor":"oral-small-molecules"},{"level":3,"text":"Cardiovascular, kidney and heart-failure outcomes","anchor":"cardiovascular-kidney-and-heart-failure-outcomes"},{"level":3,"text":"Liver: MASLD and MASH","anchor":"liver-masld-and-mash"},{"level":3,"text":"Other indications: sleep apnea, osteoarthritis, type 1 diabetes","anchor":"other-indications-sleep-apnea-osteoarthritis-type-1-diabetes"},{"level":3,"text":"Neuropsychiatric and addiction outcomes","anchor":"neuropsychiatric-and-addiction-outcomes"},{"level":3,"text":"Real-world effectiveness, persistence and cost","anchor":"real-world-effectiveness-persistence-and-cost"},{"level":3,"text":"Quantitative benchmarks","anchor":"quantitative-benchmarks"},{"level":2,"text":"Open problems and active debates","anchor":"open-problems-and-active-debates"},{"level":2,"text":"Major programs and players","anchor":"major-programs-and-players"},{"level":2,"text":"Outlook: what to watch (November 2026 - April 2028)","anchor":"outlook-what-to-watch-november-2026-april-2028"},{"level":2,"text":"Key papers","anchor":"key-papers"},{"level":2,"text":"Glossary","anchor":"glossary"}],"sample_claims":["Once-weekly semaglutide 2.4 mg produced a mean body-weight change of -14.9% vs -2.4% with placebo at 68 weeks in adults with overweight or obesity without diabetes (STEP 1, n=1,961).","Tirzepatide 5, 10 and 15 mg produced mean weight changes of -15.0%, -19.5% and -20.9% vs -3.1% with placebo at 72 weeks (SURMOUNT-1, treatment-regimen estimand)."],"includes":["markdown","claims","timeline","benchmarks","open_problems","key_papers","glossary","bibliography"],"citation_count":100,"how_to_buy":"GET https://space-kitty.com/api/v1/dossiers/glp1-metabolic with an x402 client ($0.20, USDC on Base Sepolia (testnet))."}